中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

44 records (took 0.022 seconds)

    BUBBLE DETECTOR AND RELATED BUBBLE DETECTION METHODOLOGY FOR A MEDICATION FLUID INFUSION SYSTEM
    12.
    发明申请
    BUBBLE DETECTOR AND RELATED BUBBLE DETECTION METHODOLOGY FOR A MEDICATION FLUID INFUSION SYSTEM 有权

    公开(公告)号：US20210060242A1

    公开(公告)日：2021-03-04

    申请号：US16552975

    申请日：2019-08-27

    Applicant: MEDTRONIC MINIMED, INC.

    Inventor： Davy Tong ,  Hsi C. Fusselman ,  Sarnath Chattaraj

    IPC: A61M5/168 ,  A61M5/142 ,  A61M5/36

    Abstract: A bubble detector, a medical device system that includes the detector, and a related operating methodology are disclosed here. The detector is designed and operated to detect presence of bubbles in a fluid delivery tube. The detector includes a capacitive sensor, a control circuit to control operation of the sensor to measure capacitance associated with fluid in the fluid delivery tube, a power source to provide voltage across the capacitor electrodes and to provide operating power to the control circuit, a communication module to communicate sensor data from the detector, and a housing with structural features to secure the detector to the fluid delivery tube and to maintain the capacitor electrodes in position relative to the fluid delivery tube. The sensor data is indicative of the measured capacitance associated with the fluid in the fluid delivery tube.

    METHODS AND SYSTEMS FOR INHIBITING FOREIGN-BODY RESPONSES IN DIABETIC PATIENTS
    14.
    发明申请
    METHODS AND SYSTEMS FOR INHIBITING FOREIGN-BODY RESPONSES IN DIABETIC PATIENTS 审中-公开
    抑制糖尿病患者身体反应的方法和系统

    公开(公告)号：US20150112302A1

    公开(公告)日：2015-04-23

    申请号：US14512788

    申请日：2014-10-13

    Applicant: Medtronic MiniMed, Inc.

    Inventor： Sarnath Chattaraj ,  Kiem H. Dang ,  Hsi Chung Fusselman ,  Poonam S. Gulati ,  Lance P. Hoffman ,  Guangping Zhang

    IPC: A61K31/727 ,  A61L29/16 ,  A61L29/08 ,  A61M5/142 ,  A61K38/28

    Abstract: Methods and devices are provided for reducing a diabetic patient's foreign body immune response, including infusion site-loss and/or occlusion. Such foreign body responses are associated with the treatment of the diabetic patient where the treatment requires subcutaneous implantation of a foreign body, such as a cannula or catheter. In certain embodiments of the invention, a response-inhibiting agent is administered to a patient at the site of cannula/catheter insertion, thereby facilitating delivery of insulin to the diabetic patient and mitigating site-loss and/or occlusion over a period of time.

    Abstract translation: 提供了用于减少糖尿病患者的异物免疫应答的方法和装置，包括输注部位损失和/或闭塞。 这种异物反应与治疗需要皮下植入异物如插管或导管的糖尿病患者的治疗相关联。 在本发明的某些实施方案中，在套管/导管插入部位向患者施用反应抑制剂，由此有助于将胰岛素递送至糖尿病患者并减轻一段时间的部位损失和/或闭塞。

    MEDICATION INFUSION COMPONENTS AND SYSTEMS
    16.
    发明申请
    MEDICATION INFUSION COMPONENTS AND SYSTEMS 有权

    公开(公告)号：US20250108150A1

    公开(公告)日：2025-04-03

    申请号：US18981099

    申请日：2024-12-13

    Applicant: MEDTRONIC MINIMED, INC.

    Inventor： Kiem H. Dang ,  Sarnath Chattaraj ,  Hsi C. Fusselman ,  Lance P. Hoffman ,  Guangping Zhang

    IPC: A61L29/14 ,  A61K9/00 ,  A61K31/727 ,  A61K38/28 ,  A61L29/04 ,  A61M5/142 ,  A61M5/158 ,  A61M5/38 ,  A61M25/00 ,  A61M39/10 ,  A61M39/16

    Abstract: This invention pertains to systems and components useful for infusing medications such as insulin. Typically, the components are used to deliver insulin to a diabetic patient at a site of infusion over a period of time greater than 4 days. The system components typically comprise a cannula adapted for subcutaneous insertion into a diabetic patient. The system further comprises a fluid conduit adapted to deliver the insulin solution from a medication reservoir to the site of infusion and a depot in operable contact with the fluid conduit. The depot comprises selected materials including a site-loss mitigating agent (such as heparin) which inhibits inflammation at the site of infusion, and encapsulation of the cannula at the site of infusion. The site-loss mitigating agent is not premixed with the insulin, and instead is adapted to contact the insulin solution in the depot as the insulin solution flows from the medication reservoir to the site of infusion.

    Medication infusion components and systems
    17.
    发明授权
    Medication infusion components and systems 有权

    公开(公告)号：US12201752B2

    公开(公告)日：2025-01-21

    申请号：US17499612

    申请日：2021-10-12

    Applicant: Medtronic MiniMed, Inc.

    Inventor： Kiem H. Dang ,  Sarnath Chattaraj ,  Hsi C. Fusselman ,  Lance P. Hoffman ,  Guangping Zhang

    IPC: A61L29/14 ,  A61K9/00 ,  A61K31/727 ,  A61K38/28 ,  A61L29/04 ,  A61M5/142 ,  A61M5/158 ,  A61M5/38 ,  A61M25/00 ,  A61M39/10 ,  A61M39/16

    Abstract: This invention pertains to systems and components useful for infusing medications such as insulin. Typically, the components are used to deliver insulin to a diabetic patient at a site of infusion over a period of time greater than 4 days. The system components typically comprise a cannula adapted for subcutaneous insertion into a diabetic patient. The system further comprises a fluid conduit adapted to deliver the insulin solution from a medication reservoir to the site of infusion and a depot in operable contact with the fluid conduit. The depot comprises selected materials including a site-loss mitigating agent (such as heparin) which inhibits inflammation at the site of infusion, and encapsulation of the cannula at the site of infusion. The site-loss mitigating agent is not premixed with the insulin, and instead is adapted to contact the insulin solution in the depot as the insulin solution flows from the medication reservoir to the site of infusion.

    MEDICATION INFUSION COMPONENTS AND SYSTEMS
    19.
    发明申请
    MEDICATION INFUSION COMPONENTS AND SYSTEMS 有权

    公开(公告)号：US20220409777A1

    公开(公告)日：2022-12-29

    申请号：US17823388

    申请日：2022-08-30

    Applicant: MEDTRONIC MINIMED, INC.

    Inventor： Kiem H. Dang ,  Sarnath Chattaraj ,  Hsi C. Fusselman ,  Lance P. Hoffman ,  Guangping Zhang

    IPC: A61L29/14 ,  A61K38/28 ,  A61K31/727 ,  A61L29/04 ,  A61M5/142 ,  A61M5/38 ,  A61K9/00 ,  A61M39/10 ,  A61M39/16

    Abstract: This invention pertains to systems and components useful for infusing medications such as insulin. Typically, the components are used to deliver insulin to a diabetic patient at a site of infusion over a period of time greater than 4 days. The system components typically comprise a cannula adapted for subcutaneous insertion into a diabetic patient. The system further comprises a fluid conduit adapted to deliver the insulin solution from a medication reservoir to the site of infusion and a depot in operable contact with the fluid conduit. The depot comprises selected materials including a site-loss mitigating agent (such as heparin) which inhibits inflammation at the site of infusion, and encapsulation of the cannula at the site of infusion. The site-loss mitigating agent is not premixed with the insulin, and instead is adapted to contact the insulin solution in the depot as the insulin solution flows from the medication reservoir to the site of infusion.

    IRREMOVABLE BUCKLING-RESISTANT FLEXIBLE CANNULA AND PROCESS
    20.
    发明申请
    IRREMOVABLE BUCKLING-RESISTANT FLEXIBLE CANNULA AND PROCESS 有权

    公开(公告)号：US20220401644A1

    公开(公告)日：2022-12-22

    申请号：US17352154

    申请日：2021-06-18

    Applicant: Medtronic MiniMed, Inc.

    Inventor： Davy Tong ,  Kiem H. Dang ,  Hsi C. Fusselman ,  Sarnath Chattaraj ,  Thomas P. Miller

    IPC: A61M5/142 ,  A61M5/162 ,  A61M5/172

    Abstract: A cannula includes a tubular body having an axial dimension through which a flow channel extends. The tubular body has a first end for insertion into a subject, and a second end configured to be held within a base of a medical device. The tubular body has a first length portion extending along the axial dimension from the first end toward the second end. A second length portion extends along the axial dimension from the first length portion toward the second end, and has an outer dimension that flares outward to be larger than the outer dimension of the first length portion. The second length portion also has a tubing wall thickness that is greater than the tubing wall thickness of the first length portion.

Patent Agency Ranking